Efficacy of Cangrelor as Bridging Therapy Post PCI

Title:Efficacy of Cangrelor as Bridging Therapy Post PCI

Volume: 20 Issue: 3

Author(s): Abdul A. Khan, Ghulam Murtaza*, Muhammad Khalid, Mathew Finniss and Thomas Helton

Affiliation:

• Division of Cardiovascular Medicine, East Tennessee State University, TN,United States

Keywords: Bleeding, gastrointestinal, surgery, antiplatelet, coronary syndrome, hypertension.

Abstract:

Background: Dual antiplatelet therapy (DAPT) remains the cornerstone management for the prevention of acute stent thrombosis after percutaneous intervention (PCI). Situations mandating early interruption of DAPT carry a high risk of ischemic complications. Perioperative bridge therapy using Cangrelor, an intravenous P2Y2 inhibitor, may offer a potential solution. Unfortunately, evidence for its use in non-cardiac procedures is limited.

Methods: Our protocol demonstrates successful off-label use of IV Cangrelor bridge therapy in a non-cardiac surgery patient. We describe a case of a 77-year old male; triple therapy with Aspirin, Apixaban, and Ticagrelor for recent drug-eluting stent placement required immediate surgical resection of stage I colonic adenocarcinoma.

Results: Cangrelor bridge therapy was utilized both preoperatively and postoperatively without ischemic or bleeding complications. The patient tolerated exploratory laparoscopic colectomy with minimal bleeding and good post-op recovery.

Conclusion: Minimizing the interruption of DAPT therapy in high-risk patients is achievable. However, careful planning with a team-based approach involving surgeons, cardiologists and pharmacists, along with close clinical follow-up and vigilant management of anti-platelet therapy is recommended.

Cite this article as:

Khan A. Abdul , Murtaza Ghulam *, Khalid Muhammad, Finniss Mathew and Helton Thomas , Efficacy of Cangrelor as Bridging Therapy Post PCI, Cardiovascular & Hematological Disorders-Drug Targets 2020; 20 (3) . https://dx.doi.org/10.2174/1871529X20666200228114925